This document summarizes the National AIDS Control Programme (NACP) in India. It discusses the four phases of NACP from 1992 to 2024, which aim to prevent new HIV infections and provide treatment. Key aspects of NACP include targeted interventions for high-risk groups, integrated counseling and testing centers, prevention of parent-to-child transmission, post-exposure prophylaxis, coordination with tuberculosis programs, and World Health Organization treatment guidelines. The document also outlines the structure of the National AIDS Control Organization.
NACP (National AIDS Control Programme) launched on February 12 ,2014. The Objectives was:
- Reduce new infections by 50% (2007 Baseline of NACP III)
- Comprehensive care, support and treatment to all persons living with HIV/AIDS
NACP (National AIDS Control Programme) launched on February 12 ,2014. The Objectives was:
- Reduce new infections by 50% (2007 Baseline of NACP III)
- Comprehensive care, support and treatment to all persons living with HIV/AIDS
National programme for prevention and control of cancer npcdcsanjalatchi
A non-communicable disease (NCD) is a disease that is not transmissible directly from one person to another. NCDs include Parkinson's disease, autoimmune diseases, strokes, most heart diseases, most cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
Viral Hepatitis Control Programme with Latest additions !!! This presentation has maximum latest additions from GoI programme guidelines . Original ppt has been modified according to local needs . Feel free to share and use with modifications if needed
INTRODUCTION
HISTORY OF TUBERCULOSIS
NATIONAL TB CONTROL PROGRAMME
REVISED NATIONAL TB CONTROL PROGRAMME I (RNTCP- I)
DIRECTLY OBSERVED TREATMENT SHORT COURSE (DOTS)
STOP TB STRATEGY
REVISED NATIONAL TB CONTROL PROGRAMME II (RNTCP- II)
BACKGROUND FOR NSP (2012-2017)
NATIONAL STRATEGIC PLAN (2012-2017)
END TB STRATEGY
BURDEN OF TB IN INDIA – 2017
NATIONAL STRATEGIC PLAN (2017-2025)
RECENT ADVANCES IN TB CONTROL
National Program for Prevention and Control of Cancer, Diabetes, CVD and Stro...Vivek Varat
Government of India initiated a National Programme for Prevention and Control of Cancers, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) during 2010-11 after integrating the National Cancer Control Programme (NCCP) with (NPDCS).
AIDS and its vengeance saw a back seat after we achieved the zero level of growth for it. But worries regarding the people living with AIDS are still on and we need to take care of these segments in an integrated manner
National Leprosy Eradication Programme
Date of creation- Feb 2019
Authors - Dr. Madhushree Acharya, Junior Resident, Community Medicine and Family Medicine, AIIMS Bhubaneswar; Dr. Durgesh Prasad Sahoo, Senior Resident, Community Medicine and Family Medicine, AIIMS Bhubaneswar
National programme for prevention and control of cancer npcdcsanjalatchi
A non-communicable disease (NCD) is a disease that is not transmissible directly from one person to another. NCDs include Parkinson's disease, autoimmune diseases, strokes, most heart diseases, most cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
Viral Hepatitis Control Programme with Latest additions !!! This presentation has maximum latest additions from GoI programme guidelines . Original ppt has been modified according to local needs . Feel free to share and use with modifications if needed
INTRODUCTION
HISTORY OF TUBERCULOSIS
NATIONAL TB CONTROL PROGRAMME
REVISED NATIONAL TB CONTROL PROGRAMME I (RNTCP- I)
DIRECTLY OBSERVED TREATMENT SHORT COURSE (DOTS)
STOP TB STRATEGY
REVISED NATIONAL TB CONTROL PROGRAMME II (RNTCP- II)
BACKGROUND FOR NSP (2012-2017)
NATIONAL STRATEGIC PLAN (2012-2017)
END TB STRATEGY
BURDEN OF TB IN INDIA – 2017
NATIONAL STRATEGIC PLAN (2017-2025)
RECENT ADVANCES IN TB CONTROL
National Program for Prevention and Control of Cancer, Diabetes, CVD and Stro...Vivek Varat
Government of India initiated a National Programme for Prevention and Control of Cancers, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) during 2010-11 after integrating the National Cancer Control Programme (NCCP) with (NPDCS).
AIDS and its vengeance saw a back seat after we achieved the zero level of growth for it. But worries regarding the people living with AIDS are still on and we need to take care of these segments in an integrated manner
National Leprosy Eradication Programme
Date of creation- Feb 2019
Authors - Dr. Madhushree Acharya, Junior Resident, Community Medicine and Family Medicine, AIIMS Bhubaneswar; Dr. Durgesh Prasad Sahoo, Senior Resident, Community Medicine and Family Medicine, AIIMS Bhubaneswar
Acquired immunodeficiency syndrome (AIDS) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV). By damaging your immune system, HIV interferes with your body's ability to fight infection and disease.
The National AIDS Control Programme (NACP), launched in 1992, is being implemented as a comprehensive programme for prevention and control of HIV/AIDS in India. Over time, the focus has shifted from raising awareness to behavior change, from a national response to a more decentralized response and to increasing involvement of NGOs and networks of PLHIV.
NATIONAL AIDS CONTROL PROGRAMME(NACP) PPT BY KRITIKA.pptxKritikaDhawan9
Acquired immunodeficiency syndrome (AIDS) is a chronic , potentially life, threating condition caused by the human immunodeficiency virus(HIV), a human retrovirus . By, damaging your immune system , HIV interferes with your body's ability to fight infection and disease.
HIV uses the machinery of the CD4 cells to multiply and spread throughout the body .
NATIONAL AIDS CONTROL PROGRAM
1992- - NACP 1 launched to show down the spread of HIV infection
- national AIDS control board constituted
- NACO setup
1999- - NACP 2 begins focusing on behaviour change , increased decentralization and NGO involvement.
- state AIDS control societies developed .
2002- - national AIDS control policy adopted.
- national blood policy adopted.
2004- - antiretroviral treatment initiated .
2006- - national council on AIDS constituted under chairmanship of prime minister.
- national policy on paediatric ART formulated.
2007- - NACP 3 launched for years (2007-2012)
2012- - NACP 4 launched for next 5 years
AIDSTAR-One Implementation of WHO's 2008 Pediatric HIV Treatment GuidelinesAIDSTAROne
In April 2008, the WHO Technical Reference Group for Pediatric HIV/ART and Care released a series of nine updated recommendations for diagnostic testing, initiation of treatment, and appropriate treatment regimens for HIV-exposed and infected infants. This technical brief outlines practical implementation considerations for program planners and policymakers working to incorporate these recommendations into their local efforts.
http://www.aidstar-one.com/implementation_whos_2008_pediatric_hiv_treatment_guidelines
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
2. CONTENTS
Introduction
Global & Indian Scenario
AIDS Control Programmes in India(NACP I -
NACPIV)
NACO Structure
ICTC
PPTCT
PEP
HIV & TB
WHO Treatment guidelines
References
3. INTRODUCTION
AIDS(Acquired Immuno Deficiency Syndrome)
HIV(Human Immuno deficiency Virus) retrovirus
Destroys CD4+ T cells ,which fight back
No cure for HIV infection
Mode of Transmission:
1. Sexual transmission: MSM, FSW, Hetrosexual sex
2. Blood contact: Injecting drug use
3. Maternal-Foetal transmission
Incubation Period: Few months to 10yrs
Test : ELISA ,Western blot
Treatment: ART
10. MILE STONES IN AIDS CONTROL IN
INDIA
2017-2024 NACP IV extended (National Stratergic plan for
HIV/AIDS and STI’s)
11. NACP I
Aims:
-Prevent HIV transmission
- Decrease mortality & morbidity associated with HIV
-Minimize socio-economic impact
NAC headed by Health minister
NACO established in June1992
National AIDS Control Board was consituted for
approval of NACO policies
State AIDS Cells were established in all 32 states & UT’s.But the
programme was hinderedby administrative & financial
bottelenecks.
12.
13. NACP II
Aims:
-Reduce the spread through behaviour change
-Increase capacity to respond to HIV on a long term basis
National AIDS Prevention & Control Policy(2002)
Scale up targeted interventions for HRG’s in High prevalence states
National Blood Policy
Greater Involvement of people with HIV/AIDS(GIPA)
National Adolescent Education Programme(NAEP)
Introduction to Conselling, testing & PPTCT
National ART Programme
National Council on AIDS
Setting up State AIDS Control socities in all states
Inter – Ministerial group involvement
14.
15.
16.
17.
18. •Prevalence of HIV cases in Karnataka 0.47%
•PLHIV = 2.47 lakh
•No. ART Centres in Karnataka 63
•No. ART Centres in Belagavi 6
•No. PLHIV in Belgavi 32,000 Acc. to KSAPS/undp.org
19. NACP III
Goal: Halting & reversing the epidemic by end of
theproject.
Aims:
-Prevention among HRG’s & general population
- Care Support & Treatment
Prevention – Targeted interventions(TI), ICTC, Blood
safety, communication, advocacy & mobilization &
Condom promotion
Strengthing the capacities of SAC’s & DAPCU’s
Technical support units estb.
State traning resource centres (STRC) set up.
Stratergic Information Manangement System(SIMS)
estb.
20.
21.
22. NACP IV
Aims:
-Reduce new infections by 50%
-Comprehensive Care, support & treatment to all with
HIV/AIDS
Preventive services:
-Targeted Interventions for HRG’s & Bridge Population
-Needle-syringe Exchange Programme(NSEP)
-Line Worker Scheme
-Prevention & Control of STI’s & RTI’s
-Blood Transfusion Services
-ICTC,PPCT, HIV & TB collaborative activities
-Condom Promotion
-IEC & BCC(Mass media,Folk media,Flagship programmes
like RED Ribbon Express)
23.
24.
25. NACP IV
CARE, SUPPORT & TREATMENT
-Lab services for CD4 testing, Viral Load testing,
Early Infant Diagnosis, confirmatory diagnosis of
HIV-2
-Free First & Second line treatments through Anti
Retroviral Treatment through ART centres
-Pediatric ART for Children
-Nutritional & Psycho-Social Support through
community & support centres.
-HIV-TB coordination
-Treatment of Opportunistic Infections
29. ICTC
Integrated Counselling and Testing Centre
HIV counselling and testing services were started in India in
1997. As on 31st August 2016 in India, there are 20,756 ICTC
mainly in Govt. Hospitals
Functions:
Conducting HIV diagnostic tests.
Providing basic information on the modes of HIV transmission, and
promoting behavioural change to reduce vulnerability.
Link people with other HIV prevention, care and treatment services.
30. PPTCT
Prevention of Parent to Child Transmission
PPTCT programme was launched in the country in the year
2002
The PPTCT services cover about 47 percent annual estimated
pregnancies in the country. In the year 2015-16, 12.7 million
pregnant women accessed this service. Of these, 11,918
pregnant women were HIV positive.
Functions:
Conselling & testing of pregnant women in ICTC’s.
HIV positive cases are initiated on lifelong ART treartment
The Newborns of these positive mothers are immediately put
on the ART treatment to prevent the transmission of HIV to the
newborn.
31. PEP
Post-Exposure Prophylaxis
It means taking antiretroviral medicines (ART)
after being potentially exposed to HIV to prevent
becoming infected.
PEP must be started within 72 hours after a recent
possible exposure to HIV, but the sooner you start
PEP, the better. Every hour counts. If you’re
prescribed PEP, you’ll need to take it once or twice
daily for 28 days. PEP is effective in preventing HIV
when administered correctly, but not 100%.
32. HIV-TB COORDINATION
Launched in 2001
HIV infection make an individual more prone to TB
disease.
HIV positive TB infected person has 50-60%
chances of lifetime risk of developing TB when
compared to a negative TB pt. who has risk of 10%
RNTCP & NACO deviced Joint Action Plan for HIV-
TB cood.
Its main objective as to reduce morbidity & mortality
in PLHIV by TB diseases.
33. WHO TREATMENT GUIDELINES
WHO Clinical Staging Recommendations
HIV Infected Adults & Adolescents
Clinical Stage I and II Start ART if CD4 ≤ 500
Clinical Stage III and IV Start ART irrespective of CD4 count
All Pregnant / Breast Feeding Women
All clinical Stages Start ART irrespective of CD4 count
HIV-TB Co-Infected Patients
Patients with HIV and TB co-infection (Pulmonary or
Extra Pulmonary)
Start ART irrespective of CD4 count Start ATT rst, initiate ART as early
as possible between 2 weeks-2months. For patients with CD4 below
50, ART might be initiated simultaneously with ATT with strict clinical
and laboratory monitoring
HIV-Hepatitis B/C Co-Infected Patients
HIV and HBV / HCV co-infection – without any
evidence of severe chronic liver disease
Start ART if CD4 ≤ 500
HIV and HBV / HCV co-infection – with evidence of
severe chronic liver disease
Start ART irrespective of CD4 count
HIV-Visceral Leishmaniasis (KalaAzar) Co-Infected
Patients
Patients with HIV-Visceral Leishmaniasis co-infected Start ART irrespective of CD4 count
34. NATIONAL STRATEGIC PLAN FOR HIV/AIDS
AND STI 2017 – 2024
Paving Way for AIDS free India
HIV and STI Prevention
HIV Testing and Counselling Services(ICTC)
HIV Care, Support and Treatment (CST)
Elimination of Mother to Child Transmission of HIV
and Syphilis (EMTCT)
Laboratory Services
Blood Transfusion Services
Information Education and Communication (IEC)
Monitoring, Evaluation and Surveillance
Research and Evaluation
35.
36.
37.
38. REFERENCES
Preventive & Social Medicine by K.Park
Textbook of Public Health & Community Medicine
by AFMC, Pune
Websites:
www.naco.gov.in
www.who.int/hiv/
www.evert.org
www.ksaps.gov.in
www.undp.org.in